HC Wainwright & Co. Maintains Buy on Fennec Pharmaceuticals, Raises Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju maintains a Buy rating on Fennec Pharmaceuticals (NASDAQ:FENC) and raises the price target from $17 to $18.
April 04, 2024 | 10:22 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Fennec Pharmaceuticals and raises the price target from $17 to $18.
The upgrade in the price target by a reputable analyst firm like HC Wainwright & Co. typically signals a positive outlook on the stock, suggesting potential upside. This can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100